Hybrid coronary revascularization: Time for a new comparator?

Naoki Misumida; David J. Moliterno

doi:10.1002/ccd.27503

Hybrid coronary revascularization: Time for a new comparator?

Naoki Misumida, David J. Moliterno

Internal Medicine

Research output: Contribution to journal › Editorial

1 Scopus citations

Abstract

The present meta-analysis found no significant difference between hybrid coronary revascularization (HCR) and bypass surgery (CABG) regarding intermediate-term major adverse cardiac and cerebrovascular events. HCR is feasible, historically with higher revascularization rates but less perioperative morbidity With a comparable frequency of repeat revascularization between current-generation drug-eluting stents and CABG, future trials of HCR are considering multi-vessel PCI as the new comparator.

Original language	English
Pages (from-to)	213-214
Number of pages	2
Journal	Catheterization and Cardiovascular Interventions
Volume	91
Issue number	2
DOIs	https://doi.org/10.1002/ccd.27503
State	Published - Feb 1 2018

Bibliographical note

Publisher Copyright:
© 2018 Wiley Periodicals, Inc.

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

Access to Document

10.1002/ccd.27503

Cite this

@article{460ed72fdec24b32af93e15e48a27b44,

title = "Hybrid coronary revascularization: Time for a new comparator?",

abstract = "The present meta-analysis found no significant difference between hybrid coronary revascularization (HCR) and bypass surgery (CABG) regarding intermediate-term major adverse cardiac and cerebrovascular events. HCR is feasible, historically with higher revascularization rates but less perioperative morbidity With a comparable frequency of repeat revascularization between current-generation drug-eluting stents and CABG, future trials of HCR are considering multi-vessel PCI as the new comparator.",

author = "Naoki Misumida and Moliterno, {David J.}",

note = "Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",

year = "2018",

month = feb,

day = "1",

doi = "10.1002/ccd.27503",

language = "English",

volume = "91",

pages = "213--214",

number = "2",

}

TY - JOUR

T1 - Hybrid coronary revascularization

T2 - Time for a new comparator?

AU - Misumida, Naoki

AU - Moliterno, David J.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The present meta-analysis found no significant difference between hybrid coronary revascularization (HCR) and bypass surgery (CABG) regarding intermediate-term major adverse cardiac and cerebrovascular events. HCR is feasible, historically with higher revascularization rates but less perioperative morbidity With a comparable frequency of repeat revascularization between current-generation drug-eluting stents and CABG, future trials of HCR are considering multi-vessel PCI as the new comparator.

AB - The present meta-analysis found no significant difference between hybrid coronary revascularization (HCR) and bypass surgery (CABG) regarding intermediate-term major adverse cardiac and cerebrovascular events. HCR is feasible, historically with higher revascularization rates but less perioperative morbidity With a comparable frequency of repeat revascularization between current-generation drug-eluting stents and CABG, future trials of HCR are considering multi-vessel PCI as the new comparator.

UR - http://www.scopus.com/inward/record.url?scp=85041723520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041723520&partnerID=8YFLogxK

U2 - 10.1002/ccd.27503

DO - 10.1002/ccd.27503

M3 - Editorial

C2 - 29405596

AN - SCOPUS:85041723520

SN - 1522-1946

VL - 91

SP - 213

EP - 214

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

IS - 2

ER -

Hybrid coronary revascularization: Time for a new comparator?

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this